Objective: Many psychotropic medications used to treat schizophrenia have significant
anticholinergic properties, which are linked to cognitive impairment and dementia risk in …

Background Patients with psychotic disorders are often treated with numerous medications,
many of which have anticholinergic activity. We assessed cognition in relation to the …

Objective: Schizophrenia is treated with medications that raise serum anticholinergic activity
and are known to adversely affect cognition. The authors examined the relationship between …

Antipsychotic polypharmacy and excessive dosing still prevail worldwide in the treatment of
schizophrenia, while their possible association with cognitive function has not well been …

Context Neurocognitive impairment in schizophrenia is severe and is an important predictor
of functional outcome. The relative effect of the second-generation (atypical) antipsychotic …

The aim of this study was to compare cognitive performance between schizophrenia patients
with and without treatment resistance (TRS and non-TRS patients) taking into account …

Objective To review the roles played by neurocognitive assessment in the treatment of
schizophrenia and in the design of treatment research strategies. Method A review of the …

Antipsychotic polypharmacy and high doses have been associated with poorer outcome,
longer hospital stays, and increased side effects. The present naturalistic study assessed the …

OBJECTIVE: The authors' goals were 1) to establish a clinically useful standard index of the
relative anticholinergic potency of psychiatric medications; 2) to determine which cognitive …

Cognitive impairment is a prominent feature of schizophrenia. The availability of very brief
measures may increase the use of cognitive assessment in routine care settings. We …